Abstract |
Allopurinol is a potent xanthine oxidase inhibitor that is used in hyperuricemic patients to prevent gout. It has also been shown to decrease cardiovascular complications in a myriad of cardiovascular conditions. However, studies have reported conflicting evidence on its effects on blood pressure (BP). A systematic review was conducted using Medline, PubMed, Embase, and the Cochrane Library for all the longitudinal studies that assessed the efficacy of allopurinol on systolic and diastolic BP. A total of 10 clinical studies with 738 participants were included in the analysis. Compared with the control group, systolic BP decreased by 3.3 mm Hg (95% confidence interval [CI], 1.4-5.3 mm Hg; P=.001) and diastolic BP decreased by 1.3 mm Hg (95% CI, 0.1-2.5 mm Hg; P=.03) in patients treated with allopurinol. When analysis was restricted to the higher-quality randomized controlled trials, similar changes in systolic and diastolic BPs were found: 3.3 mm Hg (95% CI, 0.8-5.8 mm Hg; P<.001) and 1.4 mm Hg (95% CI, 0.1-2.7 mm Hg; P=.04), respectively. Allopurinol is associated with a small but significant reduction in BP. This effect can be potentially exploited to aid in controlling BP in hypertensive patients with hyperuricemia.
|
Authors | Vikram Agarwal, Nidhi Hans, Franz H Messerli |
Journal | Journal of clinical hypertension (Greenwich, Conn.)
(J Clin Hypertens (Greenwich))
Vol. 15
Issue 6
Pg. 435-42
(Jun 2013)
ISSN: 1751-7176 [Electronic] United States |
PMID | 23730993
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2012 Wiley Periodicals, Inc. |
Chemical References |
- Gout Suppressants
- Allopurinol
|
Topics |
- Allopurinol
(pharmacology)
- Blood Pressure
(drug effects)
- Gout Suppressants
(pharmacology)
- Humans
- Hypertension
(drug therapy)
|